Ozempic is changing the way people eat. Snack companies are paying close attention

  • 📰 CBCNews
  • ⏱ Reading Time:
  • 52 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 99%

Argentina Noticias Noticias

Argentina Últimas Noticias,Argentina Titulares

The injectable drug Ozempic is displayed, July 1, 2023, in Houston.

With a growing number of North American adults using drugs like Ozempic and Wegovy for weight loss, food companies are carefully watching to see how the craze is impacting their bottom line — and cooking up ways to market their products toward people on the medications.With more North American adults using Ozempic and other weight-loss drugs, food companies are carefully watching to see how the craze affects their bottom line.

With a growing number of North American adults using Ozempic and other popular, injectable drugs like Wegovy, Mounjaro and Zepbound for weight loss, food companies are carefully watching to see how the craze is impacting their bottom line — and cooking up ways to market their products toward people on those medications.

Nestle is launching a line of products in the U.S. that it says are meant to be a 'companion' for people taking such medication or otherwise trying to manage their weight. "These drugs really suppress appetite food cravings. So this is resulting in an overall decrease in food consumption," he said. As for whether companies need to be concerned, Carter says it's unlikely. "I think it's just a continued evolution of the consumer purchase behaviour as it relates to food."Nestle, for example, says the product line it's launching in the U.S. is meant to be a "companion" for people taking GLP-1 medication or otherwise trying to manage their weight.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 2. in AR
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

Argentina Últimas Noticias, Argentina Titulares